To evaluate the effectiveness and safety of TP21 injection for TACE in treatment of
hepatocellular carcinoma:
1. Primary efficacy endpoint: progression-free survival (PFS), which will be assessed by
the Independent Review Committee according to the modified Response Evaluation Criteria
in Solid Tumors (mRECIST).
2. Secondary efficacy endpoints: PFS, objective response rate (ORR), disease control rate
(DCR), overall survival (OS), time to progression (TTP), 1-year progression-free
survival, 1-year survival and 2-year survival assessed by the investigator.